Related Experiment Video
Updated: Jan 10, 2026
05:10
Multidisciplinary Approach to Obesity Management: A Case Report
Published on: May 30, 2025
885
Beyond Weight Loss: Optimizing GLP-1 Receptor Agonist Use in Children
Hussein Zaitoon1, Aimee D Wauters1, Luisa M Rodriguez1
1Division of Pediatric Endocrinology and Diabetes, University of Texas Health Science Center, San Antonio, TX 78229, USA.
Children (Basel, Switzerland)
|November 27, 2025
Summary
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) show promise for pediatric obesity and type 2 diabetes (T2D), effectively reducing weight and BMI. However, careful monitoring is crucial due to potential impacts on musculoskeletal health and nutritional status.
Area of Science:
- Pediatric Endocrinology
- Pharmacology
- Metabolic Disorders
Background:
- Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are increasingly used for pediatric obesity and type 2 diabetes (T2D).
- Evidence synthesis is needed to evaluate their efficacy and safety in children and adolescents.
Purpose of the Study:
- To review current evidence on GLP-1RA efficacy and safety in pediatric obesity and T2D.
- To identify knowledge gaps and guide future research for pediatric anti-obesity therapies.
Main Methods:
- Structured review of randomized controlled trials, extension studies, and mechanistic investigations.
- Focused on outcomes including body weight, BMI, body composition, glycemic control, and adverse events in pediatric populations.
Main Results:
- GLP-1RAs (liraglutide, semaglutide) significantly reduce BMI and weight in adolescents and younger children.
- Weight loss includes lean mass; potential risks include impaired muscle strength and bone density without exercise and adequate protein.
- Gastrointestinal events are common; long-term effects on growth, puberty, and nutritional status remain largely unaddressed.
Conclusions:
- GLP-1RAs are a valuable adjunct to lifestyle interventions for pediatric obesity.
- Pediatric-specific protocols are essential to address musculoskeletal health, nutritional adequacy, and misuse.
- Further research is critical for pediatric pharmacokinetics, dosing, and long-term developmental safety to establish evidence-based guidelines.
Related Concept Videos
01:24Glucagon-like Receptor Agonists
824
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
824
01:06Oral Hypoglycemic Agents: Glinides
573
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
573
01:16Insulin: Dosing Regimen and Adverse Effects
663
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
663
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
567
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
567
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
232
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
232
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
179
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
179